More NewsRead More
Intellipharmaceutics Reports Update on Rexista™ XR: FDA Grants Waiver of NDA Filing Fee, and Topline Pharmacokinetics Results Indicate No Food Effect
July 05, 2016
Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
May 27, 2016
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
May 26, 2016
Intellipharmaceuticals International's CFO Domenic Della Penna Interviewed by The Life Sciences Report
May 12, 2016
Intellipharmaceutics Reports Director Election Results
April 19, 2016
Intellipharmaceutics Announces First Quarter 2016 Results
April 15, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here